Microbiome-wide association studies link dynamic microbial consortia to disease

Nature

Volumn 535, Issue 7610, 2016, Pages 94-103

  Gilbert, Jack A ^a   Quinn, Robert A ^b,c,d   Debelius, Justine ^e   Xu, Zhenjiang Z ^e   Morton, James ^f   Garg, Neha ^b,c   Jansson, Janet K ^g   Dorrestein, Pieter C ^b,c,d,e   Knight, Rob ^d,e,f  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^e UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g PACIFIC NORTHWEST NATIONAL LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BIOLOGICAL MARKER; DISEASE MODIFYING ANTIRHEUMATIC DRUG; DNA; PARACETAMOL; PREBIOTIC AGENT; PROBIOTIC AGENT;

BIOCHEMISTRY; COMPLEXITY; DISEASE; GENOME; METABOLISM; MICROBIAL ACTIVITY; PROTEOMICS;

AUTISM; CARDIOVASCULAR DISEASE; CHEMISTRY; CLINICAL DECISION MAKING; CLOSTRIDIUM DIFFICILE INFECTION; COLON CANCER; CORRELATION ANALYSIS; DIAGNOSTIC TEST; DIET; DNA SEQUENCE; DRUG EFFICACY; GENETIC ASSOCIATION STUDY; GENOTYPE ENVIRONMENT INTERACTION; GLOBAL POSITIONING SYSTEM; HEALTH; HUMAN; INTESTINE FLORA; LONGITUDINAL STUDY; METABOLOME; METABOLOMICS; MICROBIAL ACTIVITY; MICROBIAL COMMUNITY; MICROBIAL CONSORTIUM; MICROBIAL POPULATION DYNAMICS; MICROBIOME; MICROBIOME WIDE ASSOCIATION STUDY; MICROORGANISM; NONHUMAN; PEPTOCLOSTRIDIUM DIFFICILE; PRIORITY JOURNAL; PROTEOMICS; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; STRATIFICATION; TAXONOMY; TIME SERIES ANALYSIS; ANIMAL; BACTERIUM; CLASSIFICATION; DISEASE PREDISPOSITION; DISEASES; DRUG EFFECTS; METABOLISM; PATHOGENICITY; PROGNOSIS; THERAPY;

ANIMALS; BACTERIA; BIOMARKERS; DISEASE; DISEASE SUSCEPTIBILITY; HEALTH; HUMANS; METABOLOME; MICROBIAL CONSORTIA; PROGNOSIS;

EID: 84978134353     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature18850     Document Type: Review

References (122)

1. Manichanh, C. et al. Anal gas evacuation and colonic microbiota in patients with flatulence: effect of diet. Gut 63, 401-408 (2014).
2. Frank, D. N. et al. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc. Natl Acad. Sci. USA 104, 13780-13785 (2007).
3. Lewis, J. D. et al. Inflammation, antibiotics, and diet as environmental stressors of the gut microbiome in pediatric Crohns disease. Cell Host Microbe 18, 489-500 (2015).
4. Ley, R. E., Turnbaugh, P. J., Klein, S. and Gordon, J. I. Microbial ecology: human gut microbes associated with obesity. Nature 444, 1022-1023 (2006).
5. Turnbaugh, P. J. et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444, 1027-1031 (2006).
6. Koeth, R. A. et al. Intestinal microbiota metabolism of l-carnitine, a nutrient in red meat, promotes atherosclerosis. Nature Med. 19, 576-585 (2013).
7. Kostic, A. D. et al. Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res. 22, 292-298 (2012).
8. Scher, J. U. et al. Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis. eLife 2, e01202 (2013).
9. Naseribafrouei, A. et al. Correlation between the human fecal microbiota and depression. Neurogastroenterol. Motil. 26, 1155-1162 (2014).
10. Scheperjans, F. et al. Gut microbiota are related to Parkinsons disease and clinical phenotype. Mov. Disord. 30, 350-358 (2015).
11. Kang, D. W. et al. Reduced incidence of Prevotella and other fermenters in intestinal microflora of autistic children. PLoS ONE 8, e68322 (2013).
12. Kostic, A. D., Howitt, M. R. and Garrett, W. S. Exploring host-microbiota interactions in animal models and humans. Genes Dev. 27, 701-718 (2013).
13. Barr, J. J. et al. Bacteriophage adhering to mucus provide a non-host-derived immunity. Proc. Natl Acad. Sci. USA 110, 10771-10776 (2013).
14. Haiser, H. J. et al. Predicting and manipulating cardiac drug inactivation by the human gut bacterium Eggerthella lenta. Science 341, 295-298 (2013).
15. Arthur, J. C. et al. Intestinal inflammation targets cancer-inducing activity of the microbiota. Science 338, 120-123 (2012).
16. Knights, D. et al. Bayesian community-wide culture-independent microbial source tracking. Nature Methods 8, 761-763 (2011).
17. Arumugam, M. et al. Enterotypes of the human gut microbiome. Nature 473, 174-180 (2011).
18. Gevers, D. et al. The treatment-naive microbiome in new-onset Crohns disease. Cell Host Microbe 15, 382-392 (2014).
19. Kuczynski, J. et al. Microbial community resemblance methods differ in their ability to detect biologically relevant patterns. Nature Methods 7, 813-819 (2010).
20. Friedman, J. and Alm, E. J. Inferring correlation networks from genomic survey data. PLoS Comput. Biol. 8, e1002687 (2012).
21. Lovell, D., Pawlowsky-Glahn, V., Egozcue, J. J., Marguerat, S. and Bahler, J. Proportionality: a valid alternative to correlation for relative data. PLoS Comput. Biol. 11, e1004075 (2015).
22. Knights, D., Parfrey, L. W., Zaneveld, J., Lozupone, C. and Knight, R. Humanassociated microbial signatures: examining their predictive value. Cell Host Microbe 10, 292-296 (2011).
23. Turnbaugh, P. J. et al. A core gut microbiome in obese and lean twins. Nature 457, 480-484 (2009).
24. The Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. Nature 486, 207-214 (2012).
25. Fierer, N. et al. Forensic identification using skin bacterial communities. Proc. Natl Acad. Sci. USA 107, 6477-6481 (2010).
26. Franzosa, E. A. et al. Identifying personal microbiomes using metagenomic codes. Proc. Natl Acad. Sci. USA 112, E2930-E2938 (2015).
27. Eren, A. M. et al. Oligotyping: differentiating between closely related microbial taxa using 16S rRNA gene data. Methods Ecol. Evol. 4, 1111-1119 (2013).
28. Noecker, C. et al. Metabolic model-based integration of microbiome taxonomic and metabolomic profiles elucidates mechanistic links between ecological and metabolic variation. mSystems 13, http://dx.doi.org/10.1128/mSystems.00013-15 (2015).
29. Koenigsknecht, M. J. et al. Dynamics and establishment of Clostridium difficile infection in the murine gastrointestinal tract. Infect. Immun. 83, 934-941 (2015).
30. Hsiao, E. Y. et al. Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders. Cell 155, 1451-1463 (2013).
31. Belda-Ferre, P. et al. The human oral metaproteome reveals potential biomarkers for caries disease. Proteomics 15, 3497-3507 (2015).
32. Willing, B. P. et al. A pyrosequencing study in twins shows that gastrointestinal microbial profiles vary with inflammatory bowel disease phenotypes. Gastroenterology 139, 1844-1854 (2010).
33. Erickson, A. R. et al. Integrated metagenomics/metaproteomics reveals human host-microbiota signatures of Crohns disease. PLoS ONE 7, e49138 (2012).
34. Jansson, J. et al. Metabolomics reveals metabolic biomarkers of Crohns disease. PLoS ONE 4, e6386 (2009).
35. Michail, S. et al. Altered gut microbial energy and metabolism in children with non-alcoholic fatty liver disease. FEMS Microbiol. Ecol. 91, 1-9 (2015).
36. Forslund, K. et al. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature 528, 262-266 (2015).
37. Ridaura, V. K. et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science 341, 1241214 (2013).
38. Li, H. and Jia, W. Cometabolism of microbes and host: implications for drug metabolism and drug-induced toxicity. Clin. Pharmacol. Ther. 94, 574-581 (2013).
39. Nicholson, J. K., Lindon, J. C. and Holmes, E. Metabonomics: understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 29, 1181-1189 (1999).
40. Wishart, D. S. Emerging applications of metabolomics in drug discovery and precision medicine. Nature Rev. Drug Discov. http://dx.doi.org/10.1038/nrd.2016.32 (2016).
41. da Silva, R. R., Dorrestein, P. C. and Quinn, R. A. Illuminating the dark matter in metabolomics. Proc. Natl Acad. Sci. USA 112, 12549-12550 (2015).
42. Gilbert, J. A. and Henry, C. Predicting ecosystem emergent properties at multiple scales. Environ. Microbiol. Rep. 7, 20-22 (2015).
43. Allen, L. et al. Pyocyanin production by Pseudomonas aeruginosa induces neutrophil apoptosis and impairs neutrophil-mediated host defenses in vivo. J. Immunol. 174, 3643-3649 (2005).
44. Puertollano, E., Kolida, S. and Yaqoob, P. Biological significance of short-chain fatty acid metabolism by the intestinal microbiome. Curr. Opin. Clin. Nutr. Metab. Care 17, 139-144 (2014).
45. Cimermancic, P. et al. Insights into secondary metabolism from a global analysis of prokaryotic biosynthetic gene clusters. Cell 158, 412-421 (2014).
46. Donia, M. S. et al. A systematic analysis of biosynthetic gene clusters in the human microbiome reveals a common family of antibiotics. Cell 158, 1402-1414 (2014).
47. Cummings, J. H. Fermentation in the human large intestine: evidence and implications for health. Lancet 1, 1206-1209 (1983).
48. Huda-Faujan, N. et al. The impact of the level of the intestinal short chain fatty acids in inflammatory bowel disease patients versus healthy subjects. Open Biochem. J. 4, 53-58 (2010).
49. Rios-Covian, D. et al. Intestinal short chain fatty acids and their link with diet and human health. Front. Microbiol. 7, 185 (2016).
50. Wikoff, W. R. et al. Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proc. Natl Acad. Sci. USA 106, 3698-3703 (2009).
51. Donia, M. S. and Fischbach, M. A. Small molecules from the human microbiota. Science 349, 1254766 (2015).
52. Nougayrede, J. P. et al. Escherichia coli induces DNA double-strand breaks in eukaryotic cells. Science 313, 848-851 (2006).
53. Putze, J. et al. Genetic structure and distribution of the colibactin genomic island among members of the family Enterobacteriaceae. Infect. Immun. 77, 4696-4703 (2009).
54. Buffie, C. G. et al. Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature 517, 205-208 (2015).
55. Langille, M. G. et al. Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences. Nature Biotechnol. 31, 814-821 (2013).
56. Allegretti, J. R. et al. Recurrent Clostridium difficile infection associates with distinct bile acid and microbiome profiles. Aliment. Pharmacol. Ther. 43, 1142-1153 (2016).
57. Maurice, C. F., Haiser, H. J. and Turnbaugh, P. J. Xenobiotics shape the physiology and gene expression of the active human gut microbiome. Cell 152, 39-50 (2013).
58. Mani, S., Boelsterli, U. A. and Redinbo, M. R. Understanding and modulating mammalian-microbial communication for improved human health. Annu. Rev. Pharmacol. Toxicol. 54, 559-580 (2014).
59. Wallace, B. D. et al. Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science 330, 831-835 (2010).
60. ElRakaiby, M. et al. Pharmacomicrobiomics: the impact of human microbiome variations on systems pharmacology and personalized therapeutics. OMICS 18, 402-414 (2014).
61. Clayton, T. A., Baker, D., Lindon, J. C., Everett, J. R. and Nicholson, J. K. Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism. Proc. Natl Acad. Sci. USA 106, 14728-14733 (2009). This study provided the first link between the toxicity of a drug (in this case, acetaminophen, a widely used analgesic) and microbial metabolism.
62. Wilson, I. D. Drugs, bugs, and personalized medicine: pharmacometabonomics enters the ring. Proc. Natl Acad. Sci. USA 106, 14187-14188 (2009).
63. Quinn, R. A. et al. From sample to multi-omics conclusions in under 48 hours. mSystems http://dx.doi.org/10.1128/mSystems.00038-16 (2016).
64. Lax, S. et al. Longitudinal analysis of microbial interaction between humans and the indoor environment. Science 345, 1048-1052 (2014).
65. Gibbons, S. M. et al. Ecological succession and viability of human-associated microbiota on restroom surfaces. Appl. Environ. Microbiol. 81, 765-773 (2015).
66. Korem, T. et al. Growth dynamics of gut microbiota in health and disease inferred from single metagenomic samples. Science 349, 1101-1106 (2015).
67. Quick, J. et al. Rapid draft sequencing and real-time nanopore sequencing in a hospital outbreak of Salmonella. Genome Biol. 16, 114 (2015).
68. Dominguez-Bello, M. G. et al. Partial restoration of the microbiota of cesareanborn infants via vaginal microbial transfer. Nature Med. 22, 250-253 (2016).
69. Goyal, M. S., Venkatesh, S., Milbrandt, J., Gordon, J. I. and Raichle, M. E. Feeding the brain and nurturing the mind: linking nutrition and the gut microbiota to brain development. Proc. Natl Acad. Sci. USA 112, 14105-14112 (2015).
70. Biteen, J. S. et al. Tools for the microbiome: nano and beyond. ACS Nano 10, 6-37 (2016).
71. Lima-Mendez, G. et al. Determinants of community structure in the global plankton interactome. Science 348, 1262073 (2015).
72. Sam Ma, Z. et al. Network analysis suggests a potentially evil alliance of opportunistic pathogens inhibited by a cooperative network in human milk bacterial communities. Sci. Rep. 5, 8275 (2015).
73. Backhed, F. et al. Dynamics and stabilization of the human gut microbiome during the first year of life. Cell Host Microbe 17, 690-703 (2015); erratum 17, 852 (2015).
74. The Integrative HMP (iHMP) Research Network Consortium. The Integrative Human Microbiome Project: dynamic analysis of microbiome-host omics profiles during periods of human health and disease. Cell Host Microbe 16, 276-289 (2014).
75. Vazquez-Baeza, Y., Pirrung, M., Gonzalez, A. and Knight, R. EMPeror: a tool for visualizing high-throughput microbial community data. Gigascience 2, 16 (2013).
76. Weingarden, A. et al. Dynamic changes in short- and long-term bacterial composition following fecal microbiota transplantation for recurrent Clostridium difficile infection. Microbiome 3, 10 (2015).
77. Koenig, J. E. et al. Succession of microbial consortia in the developing infant gut microbiome. Proc. Natl Acad. Sci. USA 108 (suppl. 1), 4578-4585 (2011).
78. Lozupone, C. A. et al. Meta-analyses of studies of the human microbiota. Genome Res. 23, 1704-1714 (2013).
79. Flores, G. E. et al. Temporal variability is a personalized feature of the human microbiome. Genome Biol. 15, 531 (2014).
80. Shade, A. et al. Conditionally rare taxa disproportionately contribute to temporal changes in microbial diversity. mBio 5, e01371-14 (2014).
81. DiGiulio, D. B. et al. Temporal and spatial variation of the human microbiota during pregnancy. Proc. Natl Acad. Sci. USA 112, 11060-11065 (2015).
82. Koren, O. et al. Host remodeling of the gut microbiome and metabolic changes during pregnancy. Cell 150, 470-480 (2012).
83. Wang, Z. et al. Prognostic value of choline and betaine depends on intestinal microbiota-generated metabolite trimethylamine-N-oxide. Eur. Heart J. 35, 904-910 (2014).
84. Zeevi, D. et al. Personalized nutrition by prediction of glycemic responses. Cell 163, 1079-1094 (2015).
85. Teng, F. et al. Prediction of early childhood caries via spatial-temporal variations of oral microbiota. Cell Host Microbe 18, 296-306 (2015).
86. Huang, S. et al. Predictive modeling of gingivitis severity and susceptibility via oral microbiota. ISME J. 8, 1768-1780 (2014).
87. Zhang, X. et al. The oral and gut microbiomes are perturbed in rheumatoid arthritis and partly normalized after treatment. Nature Med. 21, 895-905 (2015).
88. Ding, T. and Schloss, P. D. Dynamics and associations of microbial community types across the human body. Nature 509, 357-360 (2014).
89. Cotillard, A. et al. Dietary intervention impact on gut microbial gene richness. Nature 500, 585-588 (2013).
90. Walters, W. A., Xu, Z. and Knight, R. Meta-analyses of human gut microbes associated with obesity and IBD. FEBS Lett. 588, 4223-4233 (2014).
91. Kang, D., Shi, B., Erfe, M. C., Craft, N. and Li, H. Vitamin B12 modulates the transcriptome of the skin microbiota in acne pathogenesis. Sci. Transl. Med. 7, 293ra103 (2015).
92. Sinha, R., Abnet, C. C., White, O., Knight, R. and Huttenhower, C. The microbiome quality control project: baseline study design and future directions. Genome Biol. 16, 276 (2015).
93. Sinha, R. et al. Collecting fecal samples for microbiome analyses in epidemiology studies. Cancer Epidemiol. Biomarkers Prev. 25, 407-416 (2016).
94. Sokol, H. et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc. Natl Acad. Sci. USA 105, 16731-16736 (2008).
95. de Goffau, M. C. et al. Fecal microbiota composition differs between children with -cell autoimmunity and those without. Diabetes 62, 1238-1244 (2013).
96. Giongo, A. et al. Toward defining the autoimmune microbiome for type 1 diabetes. ISME J. 5, 82-91 (2011).
97. Kostic, A. D. et al. The dynamics of the human infant gut microbiome in development and in progression toward type 1 diabetes. Cell Host Microbe 17, 260-273 (2015).
98. Scher, J. U. et al. Periodontal disease and the oral microbiota in new-onset rheumatoid arthritis. Arthritis Rheum. 64, 3083-3094 (2012).
99. Koren, O. et al. Human oral, gut, and plaque microbiota in patients with atherosclerosis. Proc. Natl Acad. Sci. USA 108 (suppl. 1), 4592-4598 (2011).
100. Yin, J. et al. Dysbiosis of gut microbiota with reduced trimethylamine-N-oxide level in patients with large-artery atherosclerotic stroke or transient ischemic attack. J. Am. Heart Assoc. 4, e002699 (2015).
101. Tang, W. H. et al. Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease. Circ. Res. 116, 448-455 (2015).
102. Xu, R., Wang, Q. and Li, L. A genome-wide systems analysis reveals strong link between colorectal cancer and trimethylamine N-oxide (TMAO), a gut microbial metabolite of dietary meat and fat. BMC Genomics 16 (suppl. 7), S4 (2015).
103. Tang, W. H. et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N. Engl. J. Med. 368, 1575-1584 (2013).
104. Zhu, W. et al. Gut microbial metabolite TMAO enhances platelet hyperreactivity and thrombosis risk. Cell 165, 111-124 (2016).
105. Hsiao, E. Y., McBride, S. W., Chow, J., Mazmanian, S. K. and Patterson, P. H. Modeling an autism risk factor in mice leads to permanent immune dysregulation. Proc. Natl Acad. Sci. USA 109, 12776-12781 (2012).
106. Liu, Z., DeSantis, T. Z., Andersen, G. L. and Knight, R. Accurate taxonomy assignments from 16S rRNA sequences produced by highly parallel pyrosequencers. Nucleic Acids Res. 36, e120 (2008).
107. Gilbert, J. A. et al. Meeting report: the terabase metagenomics workshop and the vision of an Earth microbiome project. Stand. Genomic Sci. 3, 243-248 (2010).
108. Lozupone, C. and Knight, R. UniFrac: a new phylogenetic method for comparing microbial communities. Appl. Environ. Microbiol. 71, 8228-8235 (2005).
109. Quinn, R. A. et al. Microbial, host and xenobiotic diversity in the cystic fibrosis sputum metabolome. ISME J. 10, 1483-98 (2015).
110. Ridlon, J. M., Kang, D. J., Hylemon, P. B. and Bajaj, J. S. Bile acids and the gut microbiome. Curr. Opin. Gastroenterol. 30, 332-338 (2014).
111. Gill, S. R. et al. Metagenomic analysis of the human distal gut microbiome. Science 312, 1355-1359 (2006).
112. Qin, J. et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 464, 59-65 (2010).
113. Turnbaugh, P. J. et al. The human microbiome project. Nature 449, 804-810 (2007).
114. White, J. R., Nagarajan, N. and Pop, M. Statistical methods for detecting differentially abundant features in clinical metagenomic samples. PLoS Comput. Biol. 5, e1000352 (2009).
115. Love, M. I., Huber, W. and Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).
116. Mandal, S. et al. Analysis of composition of microbiomes: a novel method for studying microbial composition. Microb. Ecol. Health Dis. 26, 27663 (2015).
117. Knights, D., Costello, E. K. and Knight, R. Supervised classification of human microbiota. FEMS Microbiol. Rev. 35, 343-359 (2011).
118. Ley, R. E. et al. Obesity alters gut microbial ecology. Proc. Natl Acad. Sci. USA 102, 11070-11075 (2005).
119. Vijay-Kumar, M. et al. Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science 328, 228-231 (2010).
120. Parks, B. W. et al. Genetic control of obesity and gut microbiota composition in response to high-fat, high-sucrose diet in mice. Cell Metab. 17, 141-152 (2013).
121. Yatsunenko, T. et al. Human gut microbiome viewed across age and geography. Nature 486, 222-227 (2012).
122. Goodrich, J. K. et al. Human genetics shape the gut microbiome. Cell 159, 789-799 (2014).